Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation

Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate–binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end‐stage liver disease. Reports have described recurrent cholestasis in PFIC2 patients after transplantation, and this has been associated with immunoglobulin G antibodies to BSEP. High‐titer anti‐BSEP antibodies appear to correlate with episodes of cholestatic graft dysfunction. There is no established paradigm for treating antibody‐mediated posttransplant BSEP disease. It appears to be refractory to changes in immunosuppressant medications that would typically be effective in treating allograft rejection. Taking what is known about its pathophysiology, we designed a treatment consisting of rituximab, a chimeric monoclonal anti‐CD20 antibody, in combination with intravenous immunoglobulin and plasmapheresis. Using this approach, we report the successful management of 2 patients with antibody‐mediated recurrence of PFIC2 after LT. Liver Transpl 19:1403‐1410, 2013. © 2013 AASLD.

[1]  P. Socha,et al.  Progressive familial intrahepatic cholestasis and inborn errors of bile acid synthesis. , 2012, Clinics and research in hepatology and gastroenterology.

[2]  J. Kuebler,et al.  Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. , 2012, Journal of pediatric surgery.

[3]  B. Stieger,et al.  Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2. , 2010, Journal of hepatology.

[4]  H. Arnell,et al.  Follow-up in Children With Progressive Familial Intrahepatic Cholestasis After Partial External Biliary Diversion , 2010, Journal of pediatric gastroenterology and nutrition.

[5]  Richard J. Thompson,et al.  Recurrent low gamma‐glutamyl Transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease) , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  M. López-Santamaría,et al.  Recurrence of bile salt export pump deficiency after liver transplantation. , 2009, The New England journal of medicine.

[7]  D. Häussinger,et al.  De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: A novel mechanism of cholestasis , 2009, Hepatology.

[8]  Richard J. Thompson,et al.  Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre‐messenger RNA splicing , 2009, Hepatology.

[9]  Richard J. Thompson,et al.  Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.

[10]  M. Burdelski,et al.  Liver transplantation in children with progressive familial intrahepatic cholestasis. , 2007, Transplantation.

[11]  B. Shneider.  Progressive intrahepatic cholestasis: Mechanisms, diagnosis and therapy , 2004, Pediatric transplantation.

[12]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[13]  P. Whitington,et al.  Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. , 1988, Gastroenterology.

[14]  B. Mullock,et al.  Sources of proteins in human bile. , 1985, Gut.

[15]  A. McPherson,et al.  Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. , 1982, The Journal of clinical investigation.